患者坚持长期阿仑膦酸钠治疗的原因
研究纳入204例长期使用阿仑膦酸钠的患者,其中65例坚持治疗超过5年(C组),139例年龄匹配的已停药患者(S组)。问卷及多因素分析显示,教育水平和疾病认知与坚持治疗相关,而健康状况恶化(查尔森合并症指数升高)与停药相关。
要点
- 疾病认知与坚持长期阿仑膦酸钠治疗相关(OR=0.20,95%CI 0.045-0.93,p=0.04)。
- 较高教育水平与坚持治疗相关(OR=0.526,95%CI 0.345-0.801,p=0.003)。
- 查尔森合并症指数恶化与停药相关(OR=2.75,95%CI 1.033-7.324,p=0.04)。
核心结论
- 教育与疾病认知与长期阿仑膦酸钠治疗依从性相关,而竞争性健康问题对依从性有负面影响。
研究设计与样本
- 研究纳入204例长期使用阿仑膦酸钠的患者:65例仍坚持治疗的门诊绝经后患者(C组,治疗年限=8.70±1.31年)与139例年龄匹配的停药患者(S组,治疗年限=8.64±1.43年)进行比较。
- 评估主要生化参数、骨密度值、骨折和查尔森合并症指数(CCI),并通过问卷分析长期坚持治疗的原因。
主要发现
- 两组在基线DXA值、骨折数量和CCI方面无显著差异。
- C组教育水平较高(C组54% vs S组35%,p=0.001)。
- 访谈时,S组CCI为2的患者数量较治疗开始时显著增多(56% vs 43%,p=0.04),同时服用超过3种药物的患者数量也较基线评估时增多(22% vs 11%,p=0.01)。
- 47%的患者报告治疗期间新发疾病是停用阿仑膦酸钠的主要原因。
- 多因素逐步逻辑回归分析显示,疾病认知与坚持治疗高度相关(OR=0.20;95%CI 0.045-0.93,p=0.04),其次是较高教育水平(OR=0.526,95%CI 0.345-0.801,p=0.003);CCI恶化与停药相关(OR=2.75,95%CI 1.033-7.324,p=0.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We aimed to determine patients' reasons for continuing alendronate therapy over 5 years by administering a questionnaire. Bone mineral density, fractures, drugs, Charlson comorbidity index, and lifestyle factors were also considered. Education and awareness of the disease appeared highly associated with good alendronate adherence while worsening health status with discontinuation. INTRODUCTION: Aim of this study was to investigate patients' reasons for adhering to long-term alendronate therapy (more than 5 years), as data is not available in the current literature regarding the reasons behind long-term adherence. METHODS: We studied 204 long-term adherent alendronate users: 65 postmenopausal outpatients still adherent (group C, years on treatment = 8.70 ± 1.31) were compared to 139 age-matched patients who discontinued therapy (group S, years on treatment = 8.64 ± 1.43). We evaluated main biochemical parameters, BMD values, fractures, and Charlson comorbidity index (CCI). A questionnaire was administered to analyze the reasons for long-term adherence. RESULTS: There were no significant differences between groups concerning baseline DXA values, number of fractures, and CCI. A higher education level was observed in group C (C 54% vs S 35% of patients, p = 0.001). At the time of interview, there was a significantly higher number of patients with a CCI of two in group S compared to the beginning of treatment (56% vs 43%, p = 0.04), together with a higher number of patients taking more than 3 drugs (22% vs 11%, p = 0.01) compared to basal evaluation. Forty-seven percent of patients reported new diseases during the treatment as the main reason for stopping alendronate. A multivariate, stepwise logistic regression analysis showed that awareness of the disease was highly associated with adherence (OR = 0.20; 95% CI 0.045-0.93, p = 0.04) followed by higher education (OR = 0.526, 95% CI 0.345-0.801, p = 0.003). Worsening of CCI was associated with discontinuation (OR = 2.75, 95% CI 1.033-7.324, p = 0.04). CONCLUSIONS: Education and disease awareness are associated with long-term alendronate adherence while competing health problems negatively impact adherence.
引用
- Pepe J, Cipriani C, Cecchetti V, et al. Patients' reasons for adhering to long-term alendronate therapy. Osteoporos Int. 2019. PMID: 31089764. doi:10.1007/s00198-019-05010-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。